0000812796falseDE00008127962025-02-052025-02-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):  February 5, 2025

 

Commission File No. 001-14778

 

Soligenix, Inc.

(Exact name of small business issuer as specified in its charter)

 

DELAWARE

 

41-1505029

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification Number)

 

 

 

29 Emmons Drive,

Suite B-10

Princeton, NJ

 

08540

(Address of principal executive offices)

 

(Zip Code)

(609) 538-8200

(Issuer’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $.001 per share

 

SNGX

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

w

Item 1.02 Termination of a Material Definitive Agreement.

On February 5, 2025, Soligenix, Inc. (the “Company”) and its subsidiaries repaid in full all outstanding obligations due under, and terminated, the Loan and Security Agreement (as previously amended, the “Loan Agreement”) dated December 15, 2020 with Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P. (collectively, the “Lenders”) and Pontifax Medison Finance GP, L.P., in its capacity as administrative agent and collateral agent for itself and Lenders, relating to certain term loans issued pursuant to the Loan Agreement. Upon the termination and repayment in full of all outstanding obligations under the Loan Agreement, all related liens and security interests securing the Company’s obligations under the Loan Agreement were terminated and released.  The Company did not incur any prepayment penalty with respect to the early repayment.  

In connection with the Company’s early repaying of the obligations under the Loan Agreement, Shlomo Karako, the Partner of the Lenders, stated "Pontifax provided a $10 million loan to Soligenix over four years ago, and throughout this period, we have greatly valued our positive collaboration with the company. Their professionalism and willingness to find creative solutions have been truly commendable. We are pleased to have supported Soligenix and look forward to potential future cooperation."

The material terms and conditions of the Loan Agreement were described in the Company’s Current Report on Form 8-K filed on December 16, 2020, Current Report on Form 8-K filed on April 19, 2023, and Current Report on Form 8-K filed on October 11, 2024, and such descriptions are incorporated herein by reference.

.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Soligenix, Inc. 

February 10, 2025

By:

/s/ Christopher J. Schaber 

 

 

Christopher J. Schaber, Ph.D.

President and Chief Executive Officer

(Principal Executive Officer)

3

v3.25.0.1
Document and Entity Information
Feb. 05, 2025
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Feb. 05, 2025
Entity File Number 001-14778
Entity Registrant Name Soligenix, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 41-1505029
Entity Address, Address Line One 29 Emmons Drive
Entity Address, Adress Line Two Suite B-10
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 609
Local Phone Number 538-8200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $.001 per share
Trading Symbol SNGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000812796
Amendment Flag false

Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Soligenix Charts.
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Soligenix Charts.